CTX340 Trademark

Trademark Overview

On Thursday, June 6, 2024, a trademark application was filed for CTX340 with the United States Patent and Trademark Office. The USPTO has given the CTX340 trademark a serial number of 98589121. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, December 26, 2024. This trademark is owned by CRISPR Therapeutics AG. The CTX340 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of renal and cardiovascular diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of renal and cardiovascular diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of renal and cardiovascular diseases or conditions in the field of in vivo gene editing therapy

Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
ctx340

General Information

Serial Number98589121
Word MarkCTX340
Filing DateThursday, June 6, 2024
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateThursday, December 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 14, 2025

Trademark Statements

Goods and ServicesCells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of renal and cardiovascular diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of renal and cardiovascular diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of renal and cardiovascular diseases or conditions in the field of in vivo gene editing therapy
Goods and ServicesGene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 6, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 6, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressZUG V8 6300
CH

Trademark Events

Event DateEvent Description
Thursday, June 6, 2024NEW APPLICATION ENTERED
Thursday, December 19, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 20, 2024ASSIGNED TO EXAMINER
Friday, December 20, 2024APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords

gene editing therapy vivo field diseases treatment cardiovascular renal namely